ATE172642T1 - Impfstoffe und verfahren zu ihrer herstellung - Google Patents

Impfstoffe und verfahren zu ihrer herstellung

Info

Publication number
ATE172642T1
ATE172642T1 AT92304422T AT92304422T ATE172642T1 AT E172642 T1 ATE172642 T1 AT E172642T1 AT 92304422 T AT92304422 T AT 92304422T AT 92304422 T AT92304422 T AT 92304422T AT E172642 T1 ATE172642 T1 AT E172642T1
Authority
AT
Austria
Prior art keywords
virus
vaccines
production
methods
treating
Prior art date
Application number
AT92304422T
Other languages
English (en)
Inventor
John Sidney Oxford
Original Assignee
Retroscreen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retroscreen Ltd filed Critical Retroscreen Ltd
Application granted granted Critical
Publication of ATE172642T1 publication Critical patent/ATE172642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Telephone Function (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92304422T 1991-05-17 1992-05-15 Impfstoffe und verfahren zu ihrer herstellung ATE172642T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110808A GB9110808D0 (en) 1991-05-17 1991-05-17 Aids vaccine and method for its production

Publications (1)

Publication Number Publication Date
ATE172642T1 true ATE172642T1 (de) 1998-11-15

Family

ID=10695252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92304422T ATE172642T1 (de) 1991-05-17 1992-05-15 Impfstoffe und verfahren zu ihrer herstellung

Country Status (16)

Country Link
US (1) US5698432A (de)
EP (1) EP0514199B1 (de)
JP (1) JPH05328967A (de)
KR (1) KR0149182B1 (de)
AT (1) ATE172642T1 (de)
AU (1) AU652447B2 (de)
BR (1) BR9201848A (de)
CA (1) CA2068817A1 (de)
DE (1) DE69227400T2 (de)
ES (1) ES2127203T3 (de)
GB (1) GB9110808D0 (de)
IE (1) IE921556A1 (de)
IN (1) IN174080B (de)
NZ (1) NZ242780A (de)
SG (1) SG49763A1 (de)
ZA (1) ZA923607B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525027A (en) * 1991-05-28 1996-06-11 Kabushiki Kaisha Toshiba Working robot
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
DE19520216C2 (de) * 1995-06-01 1997-04-10 Frey Rainer H Vakzine zur Prophylaxe und Therapie von AIDS, und Verfahren zur Herstellung
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
DE19916085A1 (de) * 1998-10-28 2000-05-04 Sonntag Hans Guenther Verfahren zur Herstellung eines antiviralen Mittels
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
DE60037907T2 (de) * 1999-12-20 2009-07-09 Agricultural Research Council Verfahren zur inaktivierung von mikroorganismen
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
AU2002258268A1 (en) * 2001-12-07 2003-06-17 Genexine Co., Ltd. Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
DK2368565T3 (en) 2003-07-03 2015-09-28 Hdl Therapeutics Inc Enrichment of pre-beta lipoproteins, high density
JP5535910B2 (ja) * 2007-08-28 2014-07-02 バクスター・インターナショナル・インコーポレイテッド ウイルスワクチンを生産する方法
US20130039943A1 (en) * 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
BR112014029515A2 (pt) 2012-06-01 2017-07-25 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus schmallenberg (sbv), métodos de produção e usos da mesma, virus schmallenberg, usos de seus antígenos e composição de matéria
EP2858722B8 (de) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Zusammensetzungen und verfahren zur krebsimmuntherapie
HUE043262T2 (hu) 2012-12-13 2019-08-28 Aduro Biotech Inc Meghatározott sztereokémiájú ciklikus purindinukleotidokat tartalmazó készítmények, valamint eljárások elõállításukra és alkalmazásukra
EA201592074A1 (ru) 2013-04-29 2016-02-29 Мемориал Слоан Кеттеринг Кэнсер Сентер Композиции и способы изменения сигнальной системы вторичного мессенджера
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
EP3027227A4 (de) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Stachelkristalle und modulatoren
JP5865942B2 (ja) 2014-04-16 2016-02-17 三菱電機株式会社 内燃機関のシリンダ吸入空気量推定装置および推定方法
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
EP3507367A4 (de) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2019104237A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
CA3087207A1 (en) 2017-12-28 2019-07-04 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
WO2019143955A1 (en) 2018-01-22 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly protective inactivated influenza virus vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
DE2321951C2 (de) * 1973-05-02 1975-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer Diphtherie-Vaccine
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) * 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
EP0250128A3 (de) * 1986-06-18 1988-06-08 American Registry of Pathology Von AIDS-Patienten isoliertes Virus
DE3707987A1 (de) * 1987-03-12 1988-09-22 Behringwerke Ag Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
GB8906794D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Preparation of vaccines

Also Published As

Publication number Publication date
KR920021162A (ko) 1992-12-18
DE69227400T2 (de) 1999-07-01
AU652447B2 (en) 1994-08-25
IE921556A1 (en) 1992-11-18
ZA923607B (en) 1993-02-24
EP0514199B1 (de) 1998-10-28
EP0514199A3 (en) 1993-11-10
CA2068817A1 (en) 1992-11-18
KR0149182B1 (ko) 1998-10-15
GB9110808D0 (en) 1991-07-10
IN174080B (de) 1994-09-10
US5698432A (en) 1997-12-16
SG49763A1 (en) 1998-06-15
EP0514199A2 (de) 1992-11-19
NZ242780A (en) 1994-07-26
BR9201848A (pt) 1993-01-05
AU1634092A (en) 1992-12-17
ES2127203T3 (es) 1999-04-16
JPH05328967A (ja) 1993-12-14
DE69227400D1 (de) 1998-12-03

Similar Documents

Publication Publication Date Title
ATE172642T1 (de) Impfstoffe und verfahren zu ihrer herstellung
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
DE3486160D1 (de) Modifizierte lebende pseudo-rabies-viren, diese enthaltende impfstoffe gegen pseudo-rabies, verfahren zur herstellung und verfahren zur verwendung derselben.
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
DK0702085T4 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
CY1107720T1 (el) Ιος συνδρομου πολυσυστηματικης απισχνανσεως μετα τον απογαλακτισμο απο χοιρους
DE69635871D1 (de) Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren
ATE369435T1 (de) Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen
ATE528406T1 (de) Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer
DE3684255D1 (de) Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
ATE106748T1 (de) Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
ATE187496T1 (de) Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
DE69231143D1 (de) Spezifische Nukleotidsequenz enthaltender Masernvirusvakzinstamm und Verfahren zu seiner absoluten Identifizierung
ATE16454T1 (de) Influenzavirus-vaccine, verfahren zu ihrer herstellung und verfahren zur vermehrung von influenzaviren.
DE69324645T2 (de) Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
ATE199247T1 (de) Verfahren zur herstellung von 1-aryl-1- cyanocyclobutan-derivaten
ES2048652A1 (es) Procedimientos de amplificacion de genoma para la deteccion e identificacion de secuencias genomicas relacionadas.
DE59509667D1 (de) Vakzine zur Immunisierung gegen TBE-Virusinfektionen sowie ein Verfahren zu dessen Herstellung
DE3886234D1 (de) DNA-Sequenzen, Plasmide und Mikroorganismen sowie Verfahren zur Herstellung von Chinolinsäure.
TH13476EX (th) วัคซีนและวิธีสำหรับการผลิต
DE69203192T2 (de) Verfahren zur Herstellung von N-Ethylhydroxylamin-Hydrochlorid.
CY1116153T1 (el) Ιος συνδρομου πολυσυστηματικης απισχνανσεως μετα τον απογαλακτισμο απο χοιρους

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee